GLP-1 receptor — Drug Target

All drugs that target GLP-1 receptor — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

GLP-1 Receptor Agonist [EPC] · GLP-1 receptor agonist

Marketed (4)

• Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC] · Metabolic
  Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion, both in a glucose-dependent manner, and delays gastric emptying.
• Trulicity · Eli Lilly · GLP-1 Receptor Agonist [EPC] · Metabolic
  Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying.
• Danuglipron · Pfizer · GLP-1 receptor agonist · Metabolic
  Danuglipron is a small-molecule GLP-1 receptor agonist.
• semaglutide or tirzepatide · Mayo Clinic · GLP-1 receptor agonist · Metabolic
  Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss.

Phase 3 pipeline (5)

• HPP2103-2 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
  HPP2103-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HPP2104-1 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
  HPP2104-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HCP1904-3 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
  HCP1904-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HCP1904-2 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
  HCP1904-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.
• HGP2102-1 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
  HGP2102-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.